(Q42652187)

4 November 2017

Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer (English)

1 reference

Erb-b2 receptor tyrosine kinase 2

4 November 2017

1 reference

Christina I Zito

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6668724&resulttype=core&format=json

16 May 2020

David Riches

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6668724&resulttype=core&format=json

16 May 2020

Julia Kolmakova

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6668724&resulttype=core&format=json

16 May 2020

Jan Simons

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6668724&resulttype=core&format=json

16 May 2020

Michael Egholm

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6668724&resulttype=core&format=json

16 May 2020

David F Stern

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6668724&resulttype=core&format=json

16 May 2020

publication date

1 July 2008

1 reference

Genes, Chromosomes and Cancer

4 November 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6668724&resulttype=core&format=json

16 May 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6668724&resulttype=core&format=json

16 May 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6668724&resulttype=core&format=json

16 May 2020

page(s)

633-638

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6668724&resulttype=core&format=json

The human genome project and the future of diagnostics, treatment, and prevention

16 May 2020

cites work

1 reference

12 December 2020

Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer

1 reference

12 December 2020

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases

1 reference

12 December 2020

Untangling the ErbB signalling network

1 reference

12 December 2020

The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy

1 reference

12 December 2020

A putative molecular-activation switch in the transmembrane domain of erbB2.

1 reference

12 December 2020

Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines

1 reference

12 December 2020

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

12 December 2020

Lung cancer: intragenic ERBB2 kinase mutations in tumours

1 reference

12 December 2020

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

12 December 2020

Intracellular signal transduction pathway proteins as targets for cancer therapy.

1 reference

12 December 2020

Genome sequencing in microfabricated high-density picolitre reactors

1 reference

12 December 2020

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

1 reference

12 December 2020

EGFR inhibitors: what have we learned from the treatment of lung cancer?

1 reference

12 December 2020

Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

1 reference

12 December 2020

Herceptin: mechanisms of action and resistance

1 reference

12 December 2020

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

1 reference

12 December 2020

G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene

1 reference

12 December 2020

Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors

1 reference

12 December 2020

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features

1 reference

12 December 2020

Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy

1 reference

12 December 2020

A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma

1 reference

12 December 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

12 December 2020

DNA sequencing with chain-terminating inhibitors

1 reference

12 December 2020

Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms

1 reference

12 December 2020

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

12 December 2020

Identifiers

DOI

10.1002/GCC.20566

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6668724&resulttype=core&format=json

16 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6668724&resulttype=core&format=json

16 May 2020

1 reference